WST
West Pharmaceuti (WST)
NYSE
$336.34+$6.63 (+2.01%)
Price as of Jun 23, 2026 5:39 PM EDT
  • $23.3B
    Market Cap
  • 52.65%
    1-Year Change
  • Medical Instruments & Supplies
    Industry

Key Performance

More
  • Earnings Score: 47
  • Momentum Score: 27
  • True Yield: 58
  • Financial Health Score: 32
TradeSmith Loading

Latest Research & News

Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion

The Gates Foundation Trust has completely divested from Microsoft after decades of slowly selling its position. The $31.6 billion endowment has instead added West Pharmaceutical Services (WST) to its portfolio, a healthcare stock with 32 consecutive years of dividend increases and forecasted earnings growth of 14-15% annually through 2027, positioning it as a potential future Dividend King.

06/02/2026, 6:30 PM • The Motley Fool

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report

President Trump purchased up to $680,000 in Eli Lilly shares and $250,000-$500,000 in West Pharmaceutical shares in early 2026, with purchases coinciding with new Medicare policies favoring GLP-1 obesity drugs. Eli Lilly was selected for a CMS pilot program offering GLP-1 drugs at $50/month. The Trump Organization stated investments are independently managed through discretionary accounts.

05/19/2026, 1:37 PM • Benzinga

Investors Await Damage Assessment After West Pharmaceutical Cyberattack

West Pharmaceutical Services disclosed a material cyberattack on May 7 where unauthorized parties exfiltrated data and encrypted systems. The company has restored core enterprise systems and resumed some operations, but the full scope of damage and financial impact remain unknown. William Blair maintains an Outperform rating despite near-term uncertainty, citing the company's strong market position. WST shares fell 2.02% on the news.

05/12/2026, 1:59 PM • Benzinga

Trends and Strategies in the 2026 Medical Device CMDO Market: Revenue to Exceed $354 Billion by 2033

The global medical device contract development and manufacturing organization (CDMO) market is expected to expand significantly at a CAGR of 13.12% from 2026 to 2033, driven by increased outsourcing by OEMs, demand for advanced connected devices, and the shift toward home care and minimally invasive treatments. CDMOs are becoming essential partners for managing regulatory complexities, reducing capital expenditure, and accelerating time-to-market.

04/28/2026, 10:56 AM • GlobeNewswire

West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1

West Pharmaceutical reported strong Q1 2026 results with adjusted EPS of $2.13 (beating consensus of $1.68) and net sales of $844.90 million, up 21% year-over-year. The company raised its full-year 2026 guidance for both revenue and EPS, driven by robust demand for GLP-1 injectable components which contributed 10% of total sales. The board also authorized a new $1 billion share repurchase program.

04/23/2026, 1:42 PM • Benzinga

Pharmaceutical Packaging Market to Exceed $219B by 2031 as Sustainability & Injectable Drug Packaging Reshape Industry Dynamics, Says Mordor Intelligence

The global pharmaceutical packaging market is projected to grow from USD 154.78 billion in 2025 to USD 219.08 billion by 2031, with a CAGR of 5.94%. Growth is driven by increasing demand for injectable therapies, sustainable packaging solutions, and stricter regulatory traceability requirements. Key trends include the shift toward recyclable materials, adoption of prefilled syringes, and advanced barrier systems.

03/09/2026, 3:57 AM • GlobeNewswire

Iron Mountain Projects Double-Digit Growth in 2026

Iron Mountain, US Foods, and West Pharmaceutical Services reported strong Q4 2025 earnings. Iron Mountain posted record results with 16.6% revenue growth driven by data center and digital services, projecting 10-13% revenue growth for 2026. US Foods achieved 178.8% net income growth despite softer economic conditions, while West Pharmaceutical delivered 7.5% revenue growth with strong performance in high-value product components.

02/12/2026, 10:41 AM • Investing

DraftKings, Abbott, And Applovin Are Among Top 10 Large Cap Losers Last Week (Jan. 19-Jan. 23): Are the Others in Your Portfolio?

Ten large-cap stocks experienced significant declines during the week of January 19-23, 2026. AeroVironment led losses with a 19.45% drop following a government stop work order. DraftKings fell 14.4% due to Massachusetts blocking sports-related contracts, while Abbott declined 12.23% after missing earnings expectations. Other major losers included AppLovin (14.68%), Shopify (13.51%), Flutter Entertainment (13.07%), and West Pharmaceutical Services (13.27%).

01/25/2026, 8:02 AM • Benzinga

AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines

AbbVie announced a voluntary agreement with the Trump administration to lower drug prices for Medicaid while pledging $100 billion in U.S.-based R&D and capital investments over the next decade. In exchange, the company receives tariff exemptions and protection from future pricing mandates. AbbVie also announced a $650 million licensing deal with RemeGen for cancer drug RC148 and agreed to acquire a West Pharmaceutical Services manufacturing facility in Arizona for $175 million.

01/13/2026, 8:09 AM • Benzinga

$1.22 Bn Cell Therapy Packaging Market Industry Trends and Global Forecasts to 2035: Growth Driven by Shift From Broad-Spectrum Treatments to Personalized Therapeutic Development

The global cell therapy packaging market is projected to grow from $404 million in 2025 to $1.22 billion by 2035, driven by personalized cell therapies and technological innovations in packaging solutions.

12/05/2025, 5:43 AM • GlobeNewswire

Cell Therapy Packaging Market Trends and Companies Data 2025-35

The global cell therapy packaging market is projected to grow from $419.57 million in 2025 to $1.27 billion by 2034, driven by increasing demand for cell and gene therapies, technological advancements, and specialized packaging solutions.

11/28/2025, 9:00 AM • GlobeNewswire

Medical Flexible Packaging Market Size, Trends, Segments and Regional Data (NA/EU/APAC/LA/MEA) 2025-2035

The global medical flexible packaging market is projected to grow from USD 21.48 billion in 2025 to USD 34.78 billion by 2034, with a 5.5% CAGR. Key growth drivers include rising pharmaceutical needs, sustainability focus, and increasing chronic disease prevalence.

11/19/2025, 8:00 AM • GlobeNewswire

Why West Pharmaceutical Services Stock Was Blasting Higher on Thursday

West Pharmaceutical Services reported strong Q3 2025 earnings, beating analyst expectations with nearly 8% year-over-year sales growth and raising full-year guidance, leading to an 11% stock price increase.

10/23/2025, 4:21 PM • The Motley Fool

West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand

West Pharmaceutical Services reported strong Q3 earnings, beating analyst estimates with $1.96 per share and raising fiscal 2025 guidance, driven by robust demand for GLP-1 product components.

10/23/2025, 12:16 PM • Benzinga

WEST PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against West Pharmaceutical Services for allegedly misleading investors about business performance, customer demand, and product margins during February 2023-2025 period.

10/08/2025, 3:27 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$324.68
$329.86
$329.71
1-Year Range
$210.08
$334.66
$329.71
Latest Close$329.71
Change
+$1.76 (+0.53%)
Volume842,928
Market Cap$23.3B
Shares Outstanding70.6M
P/E (TTM)44.08
Diluted EPS (TTM)$7.48
Enterprise Value$23.0B

Information as of 06/22/2026

Company Profile

WEST PHARMACEUTICAL SERVICES INC
WEST PHARMACEUTICAL SERVICES INC
https://www.westpharma.com
$23.3B
Market Cap
$542.7M
Net Income
Sector: Healthcare
Industry: Medical Instruments & Supplies
530 Herman O. West Drive, Exton, PA, United States, 19341-1147
610 594 2900

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Key Executives

  • Robert W. McMahon
  • Eric Green
  • Devesh Mathur
  • Shane Campbell
  • Annette F. Favorite

Current Ownership Distribution

  • Institutions1.2B (78.72%)
  • Mutual Funds334.4M (21.18%)
  • Insiders1.7M (0.11%)
  • Other0 (0.00%)